

Supplemental Table S2. Clinical RP2D concentrations for PARP inhibitors.

	Recommended Phase 2 dose (RP2D)	C _{min} (µg/ml)	C _{min} (µM)	C _{max} (µg/ml)	C _{max} (µM)
Veliparib	400 mg BID	0.6 ^a	2.5*	4.2 ^a	17.2*
Olaparib	400 mg BID	2 ^b	4.6*	6 ^b	13.8*
Talazoparib	1 mg QD	0.004*	0.01 ^c	0.019*	0.05 ^c
Rucaparib	600 mg BID	NR	NR	2.42 ^d	5.7*
Niraparib	300 mg QD	0.63*	1.98 ^e	0.99*	3.1 ^e
A-934935	NA	NA	NA	NA	NA

^aPuhalla S, et al J Clin Oncol 32, 2014 (supplement: Abstract 2570)

^bGupta A, et al., J Clin Oncol 30, 2012 (supplement: Abstract 3051)

^cDeBono J, et al., J Clin Oncol 31, 2013 (supplement: Abstract 2580)

^dKristeleit et al.ClinCancerRes; March 6, 2017;DOI: 10.1158/1078-0432.CCR-16-2796

^eSandu et. al., Lancet Oncol 2013; 14: 882–92

*calculated from molecular weight and reported values

NR = not reported

NA= not applicable